Replies to post #128694 on Amarin Corp Plc (AMRN)

[sharonc]

You probably need to calm down about this. Methotrexate can be toxic and people have trouble staying on it. The mechanism of action is totally different than Vascepa so the results of one trial will not be predictive of the results of the other trial. The side effect list is long for Methotrexate. You might be able to save a few from heart disease but you will kill them in other ways. It is very unlikely that the results of this trial will impact Vascepa.

[AVII77]

I really don't know.

I would like to see it stopped for efficacy. That would be a positive for humanity. What effect it would have on R-IT is questionable. It would add support to the inflammation hypothesis. But as JL notes the MOA of attacking inflammation is different.

If it failed.... well, that sucks for humanity. But, if R-IT succeeds we wouldn't have cheap competition.

If you're watching the talk, I thought the slide discussing the reduction in CVD risk in RA patients was interesting (and very fairly presented .... taking care to emphasize the data are from non-controlled observational studies).

But that talk laid out a very good case for conducting the trial. Surprised it enrolled so poorly.

The slides discussing JUPITER were also interesting.

I'd be curious to hear your view (or anyone's) after watching it.